Illumina Valuation Multiples

Illumina is valued at $40B as of October 2026, a 9.2x revenue multiple. In the last 12 months, Illumina revenue was $4.6B and Illumina EBITDA was $1.3B.

Illumina Overview

About Illumina

Illumina is a genomics company headquartered in San Diego, California, that develops and sells DNA sequencing and array-based systems for research, clinical and applied markets. It was incorporated in April 1998 by David Walt, Larry Bock, John Stuelpnagel, Anthony Czarnik and Mark Chee, and its shares trade on the Nasdaq under the symbol ILMN. Its NovaSeq, NextSeq and MiSeq sequencers and microarrays are bought by genomic research centers, pharmaceutical companies, academic institutions and clinical laboratories. Revenue comes from instrument sales and from the consumables and services used with an installed base of about 21,000 systems in 165 countries. Fiscal 2025 revenue was $4.34 billion, flat on 2024, with GAAP net income of $850 million, and the company has about 8,600 employees. It acquired the cancer-detection company GRAIL in 2021 and completed its spin-off in June 2024, keeping a 14.5% minority stake. In January 2025 it invested $20 million in Truveta alongside Regeneron to support the Truveta Genome Project.


Founded

1998

HQ

United States

Employees

10.1K

Financials (LTM)

Revenue: $4.6B
EBITDA: $1.3B

EV

$42B

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Illumina Financials

Illumina reported last 12-month revenue of $4.6B and EBITDA of $1.3B.

In the same LTM period, Illumina generated $3.1B in gross profit, $1.3B in EBITDA, and $807M in net income.

Revenue (LTM)


Illumina P&L

In the most recent fiscal year, Illumina reported revenue of $4.3B and EBITDA of $1.4B.

Illumina is profitable as of last fiscal year, with gross margin of 66%, EBITDA margin of 33%, and net margin of 20%.

See analyst estimates for Illumina
LTMLast FY202320242025202620272028
Revenue$4.6B$4.3B$4.5B$4.4B$4.3B
Gross Profit$3.1B$2.9B$2.7B$2.9B$2.9B
Gross Margin68%66%61%65%66%
EBITDA$1.3B$1.4B($666M)($771M)$1.4B
EBITDA Margin28%33%(15%)(18%)33%
EBIT Margin23%19%(5%)14%19%
Net Profit$807M$850M($1.2B)($1.2B)$850M
Net Margin18%20%(26%)(28%)20%
Net Debt-$649M---

Financial data powered by Morningstar, Inc.

Illumina Stock Performance

Illumina has current market cap of $40B, and enterprise value of $42B.

Market Cap Evolution


Illumina's stock price is $267.93.

Illumina share price decreased by 2.1% in the last 30 days, and increased by 116.9% in the last year.

Illumina has an EPS (earnings per share) of $5.63.

See more trading valuation data for Illumina
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$42B$40B-1.4%-2.1%30.6%116.9%$5.63

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Illumina Valuation Multiples

Illumina trades at 9.2x EV/Revenue multiple, and 32.5x EV/EBITDA.

See NTM and 2027E valuation multiples for Illumina

EV / Revenue (LTM)


Illumina Financial Valuation Multiples

As of October 16, 2026, Illumina has market cap of $40B and EV of $42B.

Illumina has a P/E ratio of 50.2x.

LTMLast FY202320242025202620272028
EV/Revenue9.2x9.6x9.3x9.6x9.6x
EV/EBITDA32.5x29.5x(62.8x)(54.2x)29.5x
EV/EBIT39.1x51.2x(188.4x)69.7x51.2x
EV/Gross Profit13.5x14.6x15.2x14.6x14.6x
P/E50.2x47.6x(34.8x)(33.1x)47.6x
EV/FCF47.9x44.9x147.8x59.0x44.9x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Illumina Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Illumina Margins & Growth Rates

Illumina grew revenue by 6% but EBITDA decreased by 8% in the last fiscal year.

In the most recent fiscal year, Illumina reported gross margin of 66%, EBITDA margin of 33%, and net margin of 20%.

See estimated margins and future growth rates for Illumina

Illumina Margins

Last FY202420252026202720282029
Gross Margin66%65%66%68%
EBITDA Margin33%(18%)33%28%
EBIT Margin19%14%19%24%
Net Margin20%(28%)20%18%
FCF Margin21%16%21%18%

Illumina Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth6%(3%)(1%)6%
Gross Profit Growth10%4%0%10%
EBITDA Growth(8%)16%(284%)(8%)
EBIT Growth33%(370%)36%33%
Net Profit Growth(4%)5%(170%)(4%)
FCF Growth(9%)151%31%(9%)

Data powered by FactSet, Inc. and Morningstar, Inc.

Illumina Operational KPIs

Illumina's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.2M for the same period.

Illumina's Rule of 40 is 35% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Illumina's Rule of X is 44% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Illumina
LTMLast FY202320242025202620272028
Rule of 4034%35%---
Bessemer Rule of X44%44%---
Revenue per Employee-$0.4M---
Opex per Employee-$0.2M---
R&D Expenses to Revenue21%22%30%27%22%
Opex to Revenue-48%85%84%48%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Illumina Competitors

Illumina competitors include IDEXX Laboratories, Waters, ResMed, DexCom, Mettler Toledo, Alcon, GE HealthCare, Agilent, Siemens Healthineers and Mindray.

Most Illumina public comparables operate across Life Sciences Tools, Diagnostics & Genomics, Medical Devices, BioTech, DeepTech and Longevity.

Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
IDEXX Laboratories$4.3B$1.5B10.2x9.5x29.2x26.6x
Waters$3.2B$1B15.3x8.4x48.0x25.7x
ResMed$5.7B$2.1B5.9x5.9x15.8x15.2x
DexCom$4.7B$1.3B7.0x6.4x25.8x20.3x
Mettler Toledo$4B$1.2B8.7x8.3x28.1x26.4x
Alcon$10B$2.6B3.4x3.3x13.6x12.7x
GE HealthCare$21B$3.7B2.0x1.9x10.8x10.6x
Agilent$6.9B$1.8B7.4x6.9x29.2x23.4x

This data is available for Pro users. Sign up to see all Illumina competitors and their valuation data.

Start Free Trial

Acquisitions by Illumina

Illumina has acquired 9 companies to date.

Last acquisition by Illumina was on June 23rd 2025. Illumina acquired SomaLogic for $350M (EV/Revenue multiple available to Pro users).

See M&A valuation multiples

Latest Acquisitions by Illumina

SomaLogic
Fluent BioSciences
IDbyDNA
GRAIL
Description
SomaLogic is a Boulder-headquartered proteomics company offering SOMAscan assays for biomarker discovery. Its SOMAmer reagents detect over 7,000 proteins from 100 microliters of sample, applied in oncology, cardiovascular, neurology, and metabolic research. Founded in 1999, the company partners with Pfizer and Novartis and processed samples for over 1 million subjects in studies.
Fluent BioSciences is a Boston-based life sciences firm specializing in single-cell analysis technology. Its PIPseq platform encapsulates individual cells into millions of nanoliter partitions without microfluidics, enabling next-generation sequencing of RNA and proteins. Adopted by biotech firms, pharmaceutical companies like Pfizer, and academic labs at Harvard and MIT, the technology supports high-throughput genomics research for drug discovery and immunology studies.
-
GRAIL Inc is a healthcare company focused on developing technologies for early cancer detection. The company has developed a multi-cancer early detection blood test that has the ability to detect all types of cancer, across all stages. It operates in one reportable operating segment which provides multi-cancer early detection testing and service.
HQ CountryUnited StatesUnited StatesUnited StatesUnited States
HQ City
Boulder, CO
Boston, MA
-
San Francisco, CA
Deal Date23 Jun 20259 Jul 202424 Jun 202221 Sep 2020
Valuation$350Mundisclosedundisclosed$8B
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Illumina acquisitions and their M&A valuation multiples.

Start Free Trial

Investments by Illumina

Illumina has invested in 13 companies to date.

Latest investment by Illumina was on December 11th 2025. Illumina invested in Myome in their Undisclosed stage round.

See VC round multiples

Latest Investments by Illumina

Myome
Pillar Biosciences
Truveta
Mantra Bio
Description
Myome is a genomics platform that sequences and analyzes whole genomes for disease risk identification. Users store data in a portable format accessible via HIPAA-compliant cloud for lifelong reuse in research matching. Processing occurs at CLIA-certified labs in the US, covering 100 million genetic variants. Founded in 2020 and based in Boston, Myome partners with 23andMe for ancestry-linked health insights.
Pillar Biosciences is a Natick-headquartered biotechnology firm founded in 2014 that specializes in next-generation sequencing for oncology diagnostics. Its patent-pending targeted sequencing platform paired with a proprietary data analysis toolkit delivers high sensitivity and specificity using clinical samples, enabling fast and cost-effective NGS-based cancer testing. The company distributes beta versions of its Lung and Colon Cancer Somatic Mutation Panel alongside BRCA1 and BRCA2 Germline Mutation Panels to cancer centers and labs across the United States and China for validation. This technology supports comprehensive genomic profiling to guide precision medicine in tumor and hereditary cancer detection.
Truveta is a health data company headquartered in Bellevue, Washington, founded in 2020 and owned and governed by a collective of US health systems. It aggregates de-identified electronic health record data from more than 30 member health systems, covering over 120 million patients, and provides that data and analytics to pharmaceutical, medical device, public health and academic customers. Products include the Truveta Data platform launched in 2021, the Truveta Language Model for structuring clinical data introduced in 2023, and the Truveta Genome Project launched in 2025. The company was created by Providence, Advocate Health, Tenet Healthcare and Trinity Health and introduced publicly in February 2021 with 14 founding health system members. Terry Myerson is chief executive. Truveta closed a $95 million Series A funded by its members in 2021 and raised $320 million at a valuation above $1 billion in 2025 from 17 health systems, Regeneron and Illumina. Pfizer was its first life sciences customer and Microsoft supplies its cloud and AI infrastructure.
Mantra Bio is a U.S. biotech firm engineering Targeted Exosome Vehicles for therapeutics via its REVEAL platform combining AI design, automation, and biomanufacturing. It produces exosomes targeting liver and lung tissues at gram-scale purity above 95 percent, advancing programs for metabolic diseases in phase I trials.
HQ CountryUnited StatesUnited StatesUnited StatesUnited States
HQ City
San Francisco, CA
Boston, MA
Bellevue, WA
San Francisco, CA
Deal Date11 Dec 202527 May 202513 Jan 20254 Jan 2023
RoundUndisclosed stageUndisclosed stageSeries CSeries A
Raisedundisclosed$35M$320M$9M
InvestorsDuquesne Family Office; Natera; Sequoia Capital; IlluminaSoleus Capital; IlluminaTrinity Health; Henry Ford Health; Providence Health & Services; Regeneron; Advocate Health; Illumina; CommonSpirit Health; Northwell HealthBoxGroup; 8VC; Allen & Company; Illumina; Viking Global Investors; Samsung Securities
Valuationundisclosedundisclosed$1Bundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Illumina investments and their VC round multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Illumina

When was Illumina founded?Illumina was founded in 1998.
Where is Illumina headquartered?Illumina is headquartered in United States.
How many employees does Illumina have?As of today, Illumina has over 10K employees.
Who is the CEO of Illumina?Illumina's CEO is Jacob Thaysen.
Is Illumina publicly listed?Yes, Illumina is a public company listed on Nasdaq.
What is the stock symbol of Illumina?Illumina trades under ILMN ticker.
When did Illumina go public?Illumina went public in 2000.
Who are competitors of Illumina?Illumina main competitors include IDEXX Laboratories, Waters, ResMed, DexCom, Mettler Toledo, Alcon, GE HealthCare, Agilent, Siemens Healthineers, Mindray.
What is the current market cap of Illumina?Illumina's current market cap is $40B.
What is the current revenue of Illumina?Illumina's last 12 months revenue is $4.6B.
What is the current revenue growth of Illumina?Illumina revenue growth (NTM/LTM) is 6%.
What is the current EV/Revenue multiple of Illumina?Current revenue multiple of Illumina is 9.2x.
What is the current EBITDA of Illumina?Illumina's last 12 months EBITDA is $1.3B.
What is Illumina's EBITDA margin?Illumina's last 12 months EBITDA margin is 28%.
What is the current EV/EBITDA multiple of Illumina?Current EBITDA multiple of Illumina is 32.5x.
What is the current FCF of Illumina?Illumina's last 12 months FCF is $873M.
What is Illumina's FCF margin?Illumina's last 12 months FCF margin is 19%.
What is the current EV/FCF multiple of Illumina?Current FCF multiple of Illumina is 47.9x.
How many companies Illumina has acquired to date?As of October 2026, Illumina has acquired 9 companies.
What was the largest acquisition by Illumina?$8B acquisition of GRAIL on 21st September 2020 was the largest M&A Illumina has done to date.
What companies Illumina acquired?Illumina acquired GRAIL, SomaLogic, Bluebee, Edico Genome, GenoLogics, IDbyDNA, Fluent BioSciences, Enancio, and Conexio Genomics.
In how many companies Illumina has invested to date?As of October 2026, Illumina has invested in 13 companies.
What was the last Illumina investment?On 11th December 2025 Illumina invested in Myome, participating in a Undisclosed stage round, alongside Duquesne Family Office, Natera, and Sequoia Capital.
In what companies Illumina invested in?Illumina invested in GRAIL, Truveta, Helix, Helixis, Human Longevity, Ginkgo Bioworks, Twist Bioscience, Pillar Biosciences, Mantra Bio, Prospect Bio, Vitagene, Concr, and Myome.

See public comps similar to Illumina

Lists including Illumina

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial